ERBB2 and breast carcinoma: Breast cancer represents a heterogeneous disease in oncology and the ERBB2 status has become a routine prognostic and predictive factor in standard measurements in the management of patients together with Estrogen Receptor alpha, which are expressed in up to 70% of all breast cancers [31], [32].